Novo Nordisk A/S header image

Novo Nordisk A/S

NOVO B

Equity

ISIN DK0062498333 / Valor 129508879

Nasdaq Copenhagen Equities (2026-04-22)
DKK 249.00+0.77%

Novo Nordisk A/S
UMushroom community rating:

star star star star star
3.85 19 votes No rating yet
NegativeNeutralPositive

About company

Novo Nordisk A/S, founded in 1923 and headquartered near Copenhagen, Denmark, is a leading global healthcare company specializing in the development, manufacturing, and marketing of pharmaceutical products. The company is renowned for its extensive range of diabetes care solutions, including various insulin therapies and innovative treatments aimed at improving patient outcomes. In addition to diabetes, Novo Nordisk also focuses on other therapeutic areas such as obesity, hemophilia, and growth disorders, leveraging advanced biotechnology to address unmet medical needs. Committed to research and development, Novo Nordisk invests significantly in scientific advancements to maintain its position in the competitive biopharmaceutical industry. The company's long-standing dedication to improving health through sustainable and effective treatments underscores its role as a key player in the global healthcare market.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results ():

Summarized from source with an LLMView Source

Key figures

-36.2%1Y
-57.2%3Y
8.44%5Y

Performance

57.9%1Y
45.3%3Y
39.3%5Y

Volatility

Market cap

131253 M

Market cap (USD)

Daily traded volume (Shares)

5,401,301

Daily traded volume (Shares)

1 day high/low

645.6 / 626.4

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

3.85

19 votes
Performance:
starstarstarstarstar
3.30
Innovation:
starstarstarstarstar
3.87
Society:
starstarstarstarstar
3.87
Nature:
starstarstarstarstar
3.57
Corbin Newbury
United Kingdom, 09 Nov 2025
star star star star star
.
Faraz Abedi
United Kingdom, 07 Nov 2025
star star star star star
Good upside
Jules Broglin
Switzerland, 30 Oct 2025
star star star star star
A socially impactful and financially strong healthcare innovator, combining medical leadership and sustainability with consistent long-term growth potential.

EQUITIES OF THE SAME SECTOR

Tempus AI Inc
Tempus AI Inc Tempus AI Inc Valor: 135855934
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.65%USD 55.51
Orion Oyj
Orion Oyj Orion Oyj Valor: 2553360
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.95%EUR 73.00
BioArctic AB
BioArctic AB BioArctic AB Valor: 38514501
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.20%SEK 321.60
AbbVie Inc
AbbVie Inc AbbVie Inc Valor: 20145667
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-2.25%USD 201.48
AEVIS VICTORIA SA
AEVIS VICTORIA SA AEVIS VICTORIA SA Valor: 47863410
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.82%CHF 13.50
Medartis Holding AG
Medartis Holding AG Medartis Holding AG Valor: 38620023
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.50%CHF 79.10
Penumbra Inc
Penumbra Inc Penumbra Inc Valor: 29290920
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.59%USD 332.21
Coty Inc
Coty Inc Coty Inc Valor: 1645885
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.70%USD 2.31
Dermapharm Holding SE
Dermapharm Holding SE Dermapharm Holding SE Valor: 40166352
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.33%EUR 45.75
Xlife Sciences Ltd.
Xlife Sciences Ltd. Xlife Sciences Ltd. Valor: 46192960
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-3.72%CHF 20.70